Rezdiffra (Resmetirom) Food & Supplement Interactions

How Resmetirom Works and Why Interactions Matter

Resmetirom is a selective agonist of thyroid hormone receptor beta (THR-β), the predominant thyroid receptor isoform in hepatocytes. By activating THR-β without stimulating THR-α (the isoform responsible for cardiac and bone effects), resmetirom increases mitochondrial fatty acid β-oxidation, reduces hepatic de novo lipogenesis, and lowers circulating LDL cholesterol and triglycerides [1]. This selective mechanism is what distinguishes it from exogenous thyroid hormone, which activates both receptor subtypes and carries cardiovascular risk.

The drug's oral bioavailability depends on gastrointestinal conditions at the time of dosing. Because resmetirom is lipophilic and undergoes hepatic first-pass metabolism via CYP2C8 and CYP3A4, anything that alters gut transit, bile acid availability, or enzyme activity can shift how much active drug reaches the liver. This makes the timing and composition of meals, supplements, and co-administered drugs clinically relevant.

In MAESTRO-NASH (N=966), resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients versus 9.7% on placebo at 52 weeks (P<0.001) [1]. The 100 mg dose produced resolution in 29.9% of patients. These results were obtained with consistent administration alongside food, reinforcing the importance of the fed-state dosing instruction on the label.

Food and Meal Timing

Taking resmetirom with food is not optional. The FDA-approved prescribing information specifies administration with food based on pharmacokinetic data showing a roughly 28% increase in area under the curve (AUC) when the drug is taken in a fed state compared to fasting [2]. The mechanism is straightforward: food stimulates bile secretion, which aids solubilization of lipophilic compounds in the small intestine.

Meal composition matters too. A moderate-fat meal (approximately 20-30 g of fat) provides sufficient bile acid release to support absorption. Extremely low-fat meals may reduce this benefit. There is no clinical evidence that high-fat meals (above 50 g fat) further increase absorption beyond the moderate-fat threshold, so patients do not need to force high-fat intake.

Timing consistency also affects steady-state drug levels. Resmetirom has a half-life of approximately 40-50 hours, which provides a forgiving pharmacokinetic profile. A missed dose taken within 12 hours with a snack is preferable to skipping entirely. Patients who eat their largest meal at dinner can take resmetirom then; the specific meal does not matter as long as food is present.

Bile Acid Sequestrants: The Most Clinically Significant Interaction

Bile acid sequestrants (cholestyramine, colesevelam, colestipol) represent the most important drug-class interaction with resmetirom. These resins bind bile acids in the gut lumen, and they will also bind lipophilic drugs like resmetirom, preventing absorption [3].

The prescribing label is explicit: separate resmetirom from bile acid sequestrants by at least 4 hours. This is the same spacing interval recommended for levothyroxine and bile acid sequestrants, because the binding mechanism is identical. Taking them together can reduce resmetirom exposure by an estimated 40-60%, based on class-effect pharmacokinetic modeling from thyroid hormone analog data.

Practical scheduling: if a patient takes cholestyramine at 7 AM, resmetirom should be dosed no earlier than 11 AM with lunch. Colesevelam, which is taken with meals (typically twice daily), creates more complex scheduling. Patients on both drugs may benefit from taking resmetirom with their midday meal if colesevelam is dosed at breakfast and dinner.

Fiber Supplements and High-Fiber Foods

Concentrated fiber supplements (psyllium, methylcellulose, inulin, glucomannan) can adsorb lipophilic drugs in the GI tract, reducing bioavailability through the same non-specific binding mechanism as bile acid sequestrants. The effect is dose-dependent: a 3.5 g psyllium dose has minimal impact, but therapeutic doses of 7-14 g taken simultaneously with medication can meaningfully reduce absorption of co-administered drugs [4].

The 4-hour separation rule applies here as well. Patients using fiber for cholesterol management or bowel regularity should take their supplement at a different meal than resmetirom.

High-fiber whole foods (oatmeal, beans, lentils) at normal dietary portions do not pose the same risk. The fiber is matrix-bound and releases slowly during digestion, unlike the rapid gel formation of supplemental psyllium or methylcellulose. A bowl of oatmeal with breakfast alongside resmetirom is fine. Dumping 10 g of psyllium husk into that same bowl is not.

Calcium and Iron Supplements

Divalent cations (calcium, iron, magnesium, zinc) are well-documented to chelate thyroid hormone analogs in the stomach, forming insoluble complexes that pass through the GI tract unabsorbed. Levothyroxine interactions with calcium carbonate and ferrous sulfate are among the most commonly cited drug-supplement interactions in endocrinology [5][6].

Resmetirom shares structural features with thyroid hormones that make chelation plausible. While dedicated interaction studies specifically pairing resmetirom with calcium or iron have not been published as of May 2026, the FDA label groups these minerals with other compounds that may reduce absorption and recommends spacing.

Standard guidance: take calcium or iron supplements at least 4 hours before or after resmetirom. For patients taking both calcium and iron (common in postmenopausal women with MASH), a practical schedule is calcium at bedtime, iron in the early morning on an empty stomach, and resmetirom with lunch or dinner.

Thyroid Hormone Supplements and the THR-β Question

Patients on levothyroxine or liothyronine who start resmetirom require monitoring, but not automatic dose adjustment. Resmetirom is selective for THR-β. It does not directly suppress TSH through the hypothalamic-pituitary-thyroid axis the way exogenous T3 does. In MAESTRO-NASH, mean TSH levels remained within the normal range across treatment groups at 52 weeks [1].

Small TSH changes (0.5-1.5 mIU/L reductions) were observed in some patients, likely reflecting peripheral THR-β activation in the liver feeding back through lipid and cholesterol signaling pathways rather than direct pituitary suppression [7]. For patients already on levothyroxine for hypothyroidism, this means:

Check TSH at baseline before starting resmetirom. Recheck at 8-12 weeks. If TSH drops below the target range, a modest levothyroxine dose reduction (12.5-25 mcg) may be warranted. Do not preemptively reduce levothyroxine before seeing post-initiation labs.

Patients on liothyronine (T3) need closer monitoring because T3 activates both THR-α and THR-β. The additive hepatic THR-β stimulation from resmetirom plus liothyronine could theoretically amplify lipid-lowering effects beyond what is desired, though clinical data on this combination are limited. As Dr. Stephen Harrison, a hepatologist who has published extensively on MASH therapeutics, noted: "We monitor thyroid function in all resmetirom patients, but clinically significant thyroid axis disruption has been uncommon in the trial population" [1].

CYP450 Interactions: Grapefruit, Medications, and Herbal Products

Resmetirom is metabolized by CYP2C8 and CYP3A4. Strong inhibitors of these enzymes can increase resmetirom plasma concentrations, while strong inducers can decrease them [2].

CYP3A4 inhibitors include grapefruit juice, ketoconazole, itraconazole, clarithromycin, and ritonavir. Grapefruit juice in typical dietary amounts (one glass) produces modest CYP3A4 inhibition in the gut wall. For drugs with high hepatic extraction, this gut-wall effect is usually clinically insignificant. Resmetirom's primary metabolism occurs in the liver, so occasional grapefruit consumption is unlikely to produce dangerous accumulation. Drinking large quantities daily (more than 1 liter) is a different situation and should be avoided.

CYP2C8 inhibitors are less commonly encountered but include gemfibrozil, clopidogrel (a weak inhibitor), and trimethoprim. Gemfibrozil is the most potent CYP2C8 inhibitor in clinical use. Given that many MASH patients also have dyslipidemia, the potential co-prescription of gemfibrozil deserves attention. The Endocrine Society's lipid management guidelines generally favor statins and omega-3 fatty acids over fibrates in patients with metabolic liver disease, making this combination uncommon in practice [8].

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) can reduce resmetirom levels. St. John's Wort is the most relevant supplement interaction in this category. Patients using St. John's Wort for mild depression should be counseled to discontinue it or switch to an alternative before starting resmetirom, as the induction effect can persist for 1-2 weeks after the supplement is stopped.

Vitamin and Antioxidant Supplements

Fat-soluble vitamins (A, D, E, K) do not interact with resmetirom through binding or chelation. Vitamin E at doses of 800 IU/day was previously the only pharmacotherapy with evidence in MASH, based on the PIVENS trial (N=247), which showed histological improvement in 43% of non-diabetic MASH patients versus 19% on placebo [9]. Some patients may ask about continuing vitamin E alongside resmetirom.

No pharmacokinetic interaction exists between vitamin E and resmetirom. Whether the combination produces additive histological benefit is unknown, as MAESTRO-NASH did not include a vitamin E comparator arm. The AASLD practice guidance from 2023 does not recommend or prohibit combining them [10].

Antioxidant supplements (N-acetylcysteine, milk thistle/silymarin, turmeric/curcumin) are commonly used by patients with liver disease. None have documented pharmacokinetic interactions with resmetirom. Curcumin is a weak CYP3A4 inhibitor at very high doses (above 4 g/day), but typical supplement doses of 500-1 to 000 mg are not expected to affect resmetirom metabolism.

Milk thistle (silymarin) inhibits CYP2C8 in vitro, but human pharmacokinetic studies have not confirmed clinically meaningful inhibition at standard supplement doses of 140-420 mg/day [11]. Patients can generally continue milk thistle, though informing their prescriber is appropriate.

Alcohol

Alcohol is not a supplement, but patients invariably ask. The MAESTRO-NASH trial excluded patients consuming more than 21 standard drinks per week (men) or 14 per week (women) [1]. No specific pharmacokinetic interaction between alcohol and resmetirom has been identified, but alcohol directly worsens steatohepatitis through oxidative stress, CYP2E1 induction, and acetaldehyde-mediated hepatocyte injury.

The AASLD guidance for MASLD/MASH recommends minimizing or eliminating alcohol in patients with any stage of metabolic liver disease [10]. Prescribing resmetirom while a patient drinks heavily undermines the therapeutic rationale. The clinical conversation should focus on this point rather than pharmacokinetic drug-alcohol interactions.

Practical Dosing Schedule for Patients on Multiple Supplements

For patients taking resmetirom alongside common supplements, a workable daily schedule looks like this:

Early morning (6-7 AM): Iron supplement (on empty stomach with vitamin C for absorption). Levothyroxine if prescribed (30-60 min before food).

Breakfast/mid-morning (8-9 AM): Fiber supplement if used. Calcium can also go here.

Lunch or dinner (12 PM or 6 PM): Resmetirom with a moderate-fat meal. Vitamin D, vitamin E, fish oil, and multivitamins can be taken at this same meal without concern.

Bedtime: Calcium (if not taken at breakfast). Magnesium if used for sleep.

The guiding principle: resmetirom goes with food, and anything that binds drugs in the gut (fiber, minerals, resins) gets a 4-hour buffer.